Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425584 | 0.96 | MAPT (0.47) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL5453288 | 0.79 | SNCA (0.48) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL5889177 | 0.79 | SNCA (0.48) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL498474 | 0.79 | SNCA (0.48) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL5889194 | 0.79 | SNCA (0.48) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL197157 | 0.76 | SNCA (0.50) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL7857587 | 0.73 | RAB9A (0.40) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL16140274 | 0.72 | SNCA (0.43) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL3420990 | 0.72 | KDM4E (0.53) | MAPTKDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8508163 | 0.71 | MAPT (0.42) | MAPTKDM4ERAB9ASMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245353-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJI XEROX CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| US-20120245353-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJI XEROX CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| US-8222409-B2 | Nitrogen-containing heterocyclic compound | FUJI XEROX CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222409-B2 | Nitrogen-containing heterocyclic compound | FUJI XEROX CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100234595-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJI XEROX CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234595-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJI XEROX CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234595-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | NPM1, NPR1, NOS1 | MAPT 2902/4885KDM4E 2689/4885RAB9A 1373/4885 |
| US-20120245353-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | NPM1, NPR1, NOS1 | MAPT 2902/4885KDM4E 2689/4885RAB9A 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.